Recently, the connection between T2D and MASLD has gained significant attention, with a few pieces of evidence confirming that diabetes medication could improve MASLD and liver fibrosis.6 In a network meta-analysis by Ren et al., which evaluated 26 hypoglycaemic agents for MASLD, only empagliflozin (sodium-glucose co-transporter two inhibitor agent) and liraglutide (glucagon-like peptide-1 receptor agonist [GLP-1RA] agent) showed effectiveness in reducing liver stiffness, improving liver enzyme and improving insulin resistance. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.